Reassessment of pioglitazone and bladder cancer based on FAERS database

Hai-Yan Chen Hui Zhao Jun-Jie Yang Qian Zhang Ming-Ming Yan Xiao-Yan Qiu a Department of Pharmacy,Affiliated Dongyang Hospital of Wenzhou Medical University,Dongyang,Zhejiang,P. R. Chinab Clinical Pharmacy Department,Huashan Hospital,Fudan University,Shanghai,P. R. Chinac Medical Affair Department,Affiliated Dongyang Hospital of Wenzhou Medical University,Dongyang,Zhejiang,P. R .China
DOI: https://doi.org/10.1080/14740338.2024.2390000
2024-09-21
Expert Opinion on Drug Safety
Abstract:Background The association between pioglitazone (PLZ) and bladder cancer (BC) remains controversial in several randomized control trials, meta-analyses of multiple prospective studies, and large-scale observational studies.
pharmacology & pharmacy
What problem does this paper attempt to address?